NO324430B1 - Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater. - Google Patents

Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater. Download PDF

Info

Publication number
NO324430B1
NO324430B1 NO19985981A NO985981A NO324430B1 NO 324430 B1 NO324430 B1 NO 324430B1 NO 19985981 A NO19985981 A NO 19985981A NO 985981 A NO985981 A NO 985981A NO 324430 B1 NO324430 B1 NO 324430B1
Authority
NO
Norway
Prior art keywords
insulin
human insulin
preparation according
human
des
Prior art date
Application number
NO19985981A
Other languages
English (en)
Norwegian (no)
Other versions
NO985981D0 (no
NO985981L (no
Inventor
Liselotte Langkjaer
Svend Havelund
Elsebeth Norup
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324430(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO985981D0 publication Critical patent/NO985981D0/no
Publication of NO985981L publication Critical patent/NO985981L/no
Publication of NO324430B1 publication Critical patent/NO324430B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO19985981A 1996-06-20 1998-12-18 Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater. NO324430B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK68596 1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en) 1996-06-20 1997-06-19 INSULIN PREPARATIONS CONTAINING NaCl

Publications (3)

Publication Number Publication Date
NO985981D0 NO985981D0 (no) 1998-12-18
NO985981L NO985981L (no) 1998-12-18
NO324430B1 true NO324430B1 (no) 2007-10-15

Family

ID=8096378

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985981A NO324430B1 (no) 1996-06-20 1998-12-18 Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater.

Country Status (21)

Country Link
EP (1) EP0921812B2 (cs)
JP (2) JP4404380B2 (cs)
KR (1) KR100451778B1 (cs)
CN (1) CN1120019C (cs)
AT (1) ATE208208T1 (cs)
AU (1) AU720484B2 (cs)
BR (1) BR9709845B1 (cs)
CA (1) CA2258097C (cs)
CZ (1) CZ297937B6 (cs)
DE (1) DE69708121T3 (cs)
DK (1) DK0921812T4 (cs)
ES (1) ES2167751T5 (cs)
HU (1) HU228094B1 (cs)
IL (2) IL127366A0 (cs)
NO (1) NO324430B1 (cs)
PL (1) PL189964B1 (cs)
PT (1) PT921812E (cs)
RU (1) RU2182015C2 (cs)
UA (1) UA49890C2 (cs)
WO (1) WO1997048414A1 (cs)
ZA (1) ZA975470B (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
WO2000029013A1 (en) * 1998-11-18 2000-05-25 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE60000288T2 (de) * 1999-01-26 2003-01-16 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
EP1165063A1 (en) * 1999-04-05 2002-01-02 Verteletsky, Pavel Vasilievich Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
EA004631B1 (ru) * 1999-12-16 2004-06-24 Эли Лилли Энд Компани Полипептидные композиции, обладающие повышенной стабильностью
EP2918286B1 (en) 2004-10-05 2020-03-18 Novo Nordisk A/S Pharmaceutical preparation containing insulin in crystalline as well as in solubilized form
RU2288000C1 (ru) * 2005-04-27 2006-11-27 Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН) Раствор инсулина для перорального введения
CR20170369A (es) 2008-10-17 2017-11-01 Sanofi Aventis Deutschland COMBINACIÓN DE UNA INSULINA Y UN AGONISTA DE GLP-1 (Divisional 2011-0188)
PL2498802T3 (pl) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104870469A (zh) 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
MX2016008977A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de insulina aspart estabilizadas.
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
CN105899191B (zh) 2014-01-09 2020-06-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CA3196481A1 (en) * 2020-11-16 2022-05-19 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled multi-dose injection devices without cloud point

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
SU1528496A1 (ru) * 1972-10-17 1989-12-15 Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии Дегидратирующее средство
US4783441A (en) † 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) † 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
JP2837956B2 (ja) * 1993-06-21 1998-12-16 ノボ ノルディスク アクティーゼルスカブ Ａｓｐ▲上Ｂ２８▼インスリン結晶
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
CA2258097C (en) 2011-02-08
CZ395698A3 (cs) 1999-05-12
DE69708121T3 (de) 2012-05-16
CN1222083A (zh) 1999-07-07
HUP9904031A2 (hu) 2000-04-28
KR20000022031A (ko) 2000-04-25
EP0921812A1 (en) 1999-06-16
CN1120019C (zh) 2003-09-03
RU2182015C2 (ru) 2002-05-10
HU228094B1 (en) 2012-10-29
NO985981D0 (no) 1998-12-18
JP2000513344A (ja) 2000-10-10
CZ297937B6 (cs) 2007-05-02
BR9709845B1 (pt) 2008-11-18
DK0921812T3 (da) 2002-02-11
ATE208208T1 (de) 2001-11-15
AU720484B2 (en) 2000-06-01
PT921812E (pt) 2002-04-29
CA2258097A1 (en) 1997-12-24
ES2167751T5 (es) 2012-03-30
JP2009235075A (ja) 2009-10-15
UA49890C2 (uk) 2002-10-15
IL127366A0 (en) 1999-10-28
PL330763A1 (en) 1999-05-24
BR9709845A (pt) 1999-08-10
ES2167751T3 (es) 2002-05-16
IL127366A (en) 2007-07-04
JP4404380B2 (ja) 2010-01-27
NO985981L (no) 1998-12-18
EP0921812B2 (en) 2011-12-21
DE69708121D1 (de) 2001-12-13
WO1997048414A1 (en) 1997-12-24
ZA975470B (en) 1997-12-22
EP0921812B1 (en) 2001-11-07
KR100451778B1 (ko) 2004-11-16
HUP9904031A3 (en) 2000-10-30
PL189964B1 (pl) 2005-10-31
DK0921812T4 (da) 2012-04-02
DE69708121T2 (de) 2002-08-01
AU3253697A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
NO324430B1 (no) Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater.
US5866538A (en) Insulin preparations containing NaCl
JP4472027B2 (ja) 炭水化物含有インスリン製剤
EP1506230B1 (en) Soluble formulations comprising monomeric insulin and acylated insulin
US6127334A (en) Methods for producing biphasic insulin formulations
EP1044016B1 (en) Stabilised insulin compositions
US20070190159A1 (en) Polyamino acid-based insulin preparation
RU2204411C2 (ru) Инсулиновые препараты, содержащие углеводы
MXPA98010515A (en) Insulin preparations containing so chloride
IL127365A (en) Insulin preparations containing carbohydrates

Legal Events

Date Code Title Description
MK1K Patent expired